The Procter Gamble Company

Matthew John Laufersweiler

Michael Philip Clark

Biswanath De

Jane Far-Jine Djung

Michael G Natchus

Adam Golebiowski

Todd Andrew Brugel

Michael John Janusz

Mark Sabat

Cynthia Monesa Crago Clark

The present invention relates to 2-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, having the formula: and pharmaceutical compositions thereof, and methods for controlling the level of one or more inflammation inducing cytokines selected from the group consisting of, interleukin-1 (IL-1), Tumor Necrosis Factor-&#x3b1; (TNF-&#x3b1;), interleukin-6 (IL-6), and interleukin-8 (IL-8), thereby controlling, mediating, or abating disease states affected by the level of extracellular inflammatory cytokines in humans.

6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

The present invention relates to compound which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein R comprises ethers or amines;

6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia

The present invention relates to 2-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, having the formula:and pharmaceutical compositions thereof, and methods for controlling the level of one or more inflammation inducing cytokines selected from the group consisting of, interleukin-1 (IL-1), Tumor Necrosis Factor-&#x3b1;(TNF-&#x3b1;), interleukin-6 (IL-6), and interleukin-8 (IL-8), thereby controlling, mediating, or abating disease states affected by the level of extracellular inflammatory cytokines in humans.

6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones which control inflammatory cytokines

The present invention relates to compounds which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula:wherein Ris substituted aryl; Ris substituted or unsubstituted aryl or heteroaryl.

6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Fused pyrazolone compounds which inhibit the release of inflammatory cytokines

6,7-dihydro-5H-pyrazolo&lsqb;1,2-a&rsqb;pyrazol-1-ones which control inflammatory cytokines

1,2-dihydropyrazol-3-ones which controls inflammatory cytokines

Spirocyclic-6,7-dihydro-5H-pyrazolo&lsqb;1,2-a&rsqb;pyrazol-1-ones which control inflammatory cytokines

Growing community of inventors

Morrow, OH, United States of America

Matthew John Laufersweiler